copy of dr. ellis on abemaciclib in hr-positive breast cancer
Published 6 years ago • 75 plays • Length 0:22Download video MP4
Download video MP3
Similar videos
-
1:39
dr. ellis on abemaciclib in hr-positive breast cancer
-
1:24
dr. ellis on adjuvant cdk4/6 inhibition in hr-positive breast cancer
-
0:20
copy of dr. ellis on the entrance of biosimilars into the field of oncology
-
7:09
abemaciclib for hr-positive metastatic breast cancer
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
5:04
abemaciclib fulvestrant at progression of hr mbc
-
3:09
dr mouabbi on the use of ribociclib vs abemaciclib in hr /her2– breast cancer
-
1:00
dr. ellis considers the use of biosimilars in oncology
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
0:41
priya rastogi, md, elaborates on the role of abemaciclib in hr , her2- node positive breast cancer
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
9:18
monarch 3: abemaciclib with endocrine therapy for mbc
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
7:17
abemaciclib for er mbc
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
2:58
patients’ perspectives on cdk4/6 inhibitors
-
4:45
monarch 3: abemaciclib as initial therapy for patients with hr /her2- advanced breast cancer